ScoreWhy is Halozyme Therapeutics, Inc. ?
1
High Management Efficiency with a high ROCE of 59.50%
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 23.90
3
Healthy long term growth as Operating profit has grown by an annual rate 268.88%
4
With a growth in Net Profit of 39.85%, the company declared Very Positive results in Jun 25
- The company has declared positive results for the last 6 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 547.78 MM
- INTEREST COVERAGE RATIO(Q) Highest at 5,072.89
- RAW MATERIAL COST(Y) Fallen by -6.89% (YoY)
5
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
6
Market Beating Performance
- The stock has generated a return of 52.37% in the last 1 year, much higher than market (S&P 500) returns of 12.33%
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Halozyme Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Halozyme Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Halozyme Therapeutics, Inc.
29.85%
1.03
41.29%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
45.55%
EBIT Growth (5y)
268.88%
EBIT to Interest (avg)
23.90
Debt to EBITDA (avg)
1.57
Net Debt to Equity (avg)
1.57
Sales to Capital Employed (avg)
0.51
Tax Ratio
19.77%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
59.50%
ROE (avg)
203.20%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
13.86
EV to EBIT
12.46
EV to EBITDA
10.96
EV to Capital Employed
5.99
EV to Sales
6.87
PEG Ratio
0.22
Dividend Yield
NA
ROCE (Latest)
48.11%
ROE (Latest)
100.64%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend23What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 547.78 MM
INTEREST COVERAGE RATIO(Q)
Highest at 5,072.89
RAW MATERIAL COST(Y)
Fallen by -6.89% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 4.44 times
NET SALES(Q)
Highest at USD 325.72 MM
OPERATING PROFIT(Q)
Highest at USD 222.9 MM
OPERATING PROFIT MARGIN(Q)
Highest at 68.43 %
PRE-TAX PROFIT(Q)
Highest at USD 204.94 MM
NET PROFIT(Q)
Highest at USD 165.16 MM
EPS(Q)
Highest at USD 1.33
-1What is not working for the Company
INVENTORY TURNOVER RATIO(HY)
Lowest at 1.51 times
Here's what is working for Halozyme Therapeutics, Inc.
Operating Cash Flow
Highest at USD 547.78 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Interest Coverage Ratio
Highest at 5,072.89
in the last five periodsMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Net Sales
Highest at USD 325.72 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Net Sales
At USD 325.72 MM has Grown at 20.16%
over average net sales of the previous four periods of USD 271.08 MMMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD 222.9 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at 68.43 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at USD 204.94 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 165.16 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD 1.33
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Debtors Turnover Ratio
Highest at 4.44 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -6.89% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at USD 20.46 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Here's what is not working for Halozyme Therapeutics, Inc.
Inventory Turnover Ratio
Lowest at 1.51 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
